Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Jan 30;8(1):rkae014.
doi: 10.1093/rap/rkae014. eCollection 2024.

Psoriatic arthritis: the role of self-reported non-adherence, non-trough drug levels, immunogenicity and conventional synthetic DMARD co-therapy in adalimumab and etanercept response

Philippa D K Curry  1 , Andrew P Morris  1   2 , Meghna Jani  2   3   4 , Hector Chinoy  2   4   5 , Anne Barton  1   2 , James Bluett  1   2 ; OUTPASS Collaborators
Collaborators, Affiliations

Psoriatic arthritis: the role of self-reported non-adherence, non-trough drug levels, immunogenicity and conventional synthetic DMARD co-therapy in adalimumab and etanercept response

Philippa D K Curry et al. Rheumatol Adv Pract. .

Abstract

Objective: The aim of this study was to assess the relationship between self-reported non-adherence, non-trough drug levels, immunogenicity and conventional synthetic DMARD (csDMARD) co-therapy in TNF inhibitor (TNF-i) drug response in PsA.

Methods: Serum samples and adherence questionnaires were collected at baseline, 3, 6 and 12 months for PsA patients prescribed TNF-i. Non-trough adalimumab (ADL) and etanercept (ETN) drug levels were measured at 3 and 6 months using commercially available ELISAs. Clinical response was assessed using PsA response criteria (PsARC) and change in 28-joint DAS (ΔDAS28) between baseline and 3, 6 and 12 months.

Results: In 244 PsA patients (52.5% ADL and 47.5% ETN), self-reported non-adherence was associated with PsARC non-response over 12 months using generalized estimating equation (GEE) modelling (P = 0.037). However, there was no significant difference between non-trough ADL or ETN drug levels based on self-reported non-adherence. Higher ETN levels at 3 months were associated with PsARC response at 3 (P = 0.015), 6 (P = 0.037) and 12 months (P = 0.015) and over 12 months using GEE modelling (P = 0.026). Increased ADL drug levels at 3 months were associated with greater ΔDAS28 at 3 months (P = 0.019). ADL anti-drug antibody-positive status was significantly associated with lower 3- and 6-month ADL levels (P < 0.001) and ΔDAS28 and PsARC response at 3, 6 and 12 months. Meanwhile, MTX co-therapy was associated with a reduction in immunogenicity at 3 and 6 months (P = 0.008 and P = 0.024).

Conclusion: Although both were associated with reduced response, the objectively measured non-trough drug levels showed more significant associations with drug response than self-reported non-adherence measures.

Keywords: TNF inhibitors; drug levels; drug response; immunogenicity; non-adherence; psoriatic arthritis.

PubMed Disclaimer

References

    1. Gladman DD, Ang M, Su L. et al. Cardiovascular morbidity in psoriatic arthritis. Ann Rheum Dis 2009;68:1131–5. - PubMed
    1. Kamalaraj N, El-Haddad C, Hay P, Pile K.. Systematic review of depression and anxiety in psoriatic arthritis. Int J Rheum Dis 2019;22:967–73. - PubMed
    1. Clunie G, McInnes IB, Barkham N. et al. Long-term effectiveness of tumour necrosis factor-α inhibitor treatment for psoriatic arthritis in the UK: a multicentre retrospective study. Rheumatol Adv Pract 2018;2:rky042. - PMC - PubMed
    1. D’Angiolella LS, Cortesi PA, Lafranconi A. et al. Cost and cost effectiveness of treatments for psoriatic arthritis: a systematic literature review. Pharmacoeconomics 2018;36:567–89. - PubMed
    1. Schwartzman S, Li Y, Zhou H, Palmer JB.. Economic impact of biologic utilization patterns in patients with psoriatic arthritis. Clin Rheumatol 2017;36:1579–88. - PMC - PubMed

LinkOut - more resources